Advertisement

Advertisement

News

SITC 2024: Elucidating the Therapeutically Relevant Mechanisms of TROP2 in Breast Cancer

News

SITC 2024: Update on Use of HDAC Inhibitor Plus Nivolumab in Advanced Melanoma

News

SITC 2024: Adding IL-4 Inhibitor to PD-1 Inhibitor Therapy for ER-Positive Breast Cancer

News

SITC 2024: Addition of Radiotherapy to Immunotherapy in Advanced Merkel Cell Carcinoma

Medical Literature

Neurologic Symptoms and Immunotherapy for Melanoma Brain Metastases: A View From New Zealand

News

ASCO Quality 2024: Benefits of Acupuncture in Treating Chemotherapy-Induced Peripheral Neuropathy

Medical Literature

Hypoalbuminemia: An Independent Biomarker of Immunotherapy Response in Metastatic Melanoma?

Chrysalyne Schmults, MD, on Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma: Treatment Pipeline

Sunandana Chandra, MD, on Advanced Melanoma: Targeted and Immunotherapies for Brain Metastases

View More

Advertisement

JNCCN Spotlights

UPDATE Nivolumab and Ipilimumab in Renal Cell Carcinoma

Elotuzumab

Cetuximab (Head and Neck Cancers)

View More

More

News

After PD-1 Inhibitors Fail: Is Ipilimumab an Option for Some With Metastatic Melanoma?

ASTRO 2024: Combination of High-Dose Radiotherapy and Immunotherapy for Metastatic NSCLC

SITC 2024: Comparing Types of Tumor Infiltrating Lymphocytes in Merkel Cell Carcinoma

ESMO 2024: Hypomethylation Plus Immune Checkpoint Inhibition for Metastatic Melanoma

SITC 2024: Elucidating the Therapeutically Relevant Mechanisms of TROP2 in Breast Cancer

Novel Monoclonal Antibody Under Study in Phase III Trial of Nonsquamous NSCLC

Is Immunotherapy Efficacious for Children and Adolescents With Melanoma?

Survival Outcomes in BRAF-Mutant Melanoma: BRAF/MEK vs PD-1 Inhibitors

View More

Advertisement

Published

Medical Literature

Daratumumab Combination Therapy for Relapsed or Refractory Multiple Myeloma

Ixazomib Plus Lenalidomide/Dexamethasone in Relapsed or Refractory Myeloma: China Continuation Study

Combination Treatment With or Without Transplantation in Multiple Myeloma

Impact of Subsidies on Use of Immunomodulatory Drugs in Medicare Beneficiaries With Myeloma

View More

Ongoing

CE Activities

Changing Treatment Landscape of Metastatic Head and Neck Squamous Cell Carcinoma With Anti–PD-1/PD-L1 Agents

Case Series: Defining the Role of Immunotherapy Across Melanoma Care

Tumor Mutational Burden, Neoantigens, and a Pathway to Predicting Response to Checkpoint Inhibitors

Minimizing the Impact of imAEs and Maximizing Efficacy of ICIs: AEs Affecting the Skin

View More

Available

Clinical Trials

A Study to Learn About the Effects of the Combination of Elranatamab

A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in NSCLC

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

View More

Resources

For Your Patients

ONS Immunotherapy News

ONS Immunotherapy Community

Society for Immunotherapy of Cancer Patient Resources

CancerCare on Immunotherapy

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2024 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.